The predictive impact of MDR1 expression and pre-tumor burden on molecular, cytogenetic and clinical outcome of CML patients on nilotinib therapy after imatinib failure

Autoria(s): Agrawal, M.; Erben, P.; Hanfstein, B.; Popa, J.; Hofmann, W.K.; Reynolds, J.; Robin, L.; Leitner, A.; Woodman, R.; Hochhaus, A.; Müller, M.
Data(s)

01/06/2010
Identificador

http://hdl.handle.net/10536/DRO/DU:30060090
Idioma(s)

eng
Publicador

Ferrata Storti Foundation
Relação

http://dro.deakin.edu.au/eserv/DU:30060090/reynolds-predictiveimpact-2010.pdf

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888565/
Palavras-Chave #predictive impact #MDR1 expression #pre-tumor burden #molecular outcome #cytogenetic outcome #clinical outcome #chronic myeloid leukaemia (CML) patients #nilotinib therapy #imatinib failure
Tipo

Journal Article
Acesso ao item digital